Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16305
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLim, Yen Ying-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorLaws, Simon M-
dc.contributor.authorPietrzak, Robert H-
dc.contributor.authorAmes, David-
dc.contributor.authorFowler, Christopher J-
dc.contributor.authorRainey-Smith, Stephanie R-
dc.contributor.authorSnyder, Peter J-
dc.contributor.authorBourgeat, Pierrick-
dc.contributor.authorMartins, Ralph N-
dc.contributor.authorSalvado, Olivier-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorMaruff, Paul-
dc.contributor.authorAIBL Research Group-
dc.date2016-09-01-
dc.date.accessioned2016-09-29T05:37:22Z-
dc.date.available2016-09-29T05:37:22Z-
dc.date.issued2016-11-
dc.identifier.citationJournal of Molecular Neuroscience 2016; 60(3): 362-370en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16305-
dc.description.abstractIn a group of older adults with very mild dementia, we aimed to characterize the nature and magnitude of cognitive decline as measured by the Cogstate Brief Battery, in relation to Aβ levels and hippocampal volume. Participants were characterized according to their status on the Clinical Dementia Rating (CDR) scale. A total of 308 individuals who were CDR 0 and had low cerebral Aβ levels (Aβ-), 32 individuals who were Aβ- and CDR 0.5, and 43 individuals who were Aβ+ and CDR 0.5 were included in this study. Participants completed the CogState brief battery at baseline, and at 18-, 36-, 54- and 72-month follow-up. Linear mixed model analyses indicated that relative to the Aβ- CDR 0 group, the Aβ+ CDR 0.5 group showed increased rates of memory decline and hippocampal volume loss. However, compared to the Aβ- CDR 0 group, the Aβ- CDR 0.5 group showed no changes in cognitive function or hippocampal volume over 72 months. The results of this study confirm that in individuals with very mild dementia, who also have biomarker confirmation of Aβ+, changes in cognitive function manifest primarily as deterioration in memory processing, and this is associated with hippocampal volume loss. Conversely, the absence of any cognitive decline or loss in hippocampal volume in individuals with very mild dementia but who are Aβ- suggests that some other non-AD disease process may underlie any static impairment in cognitive function.en
dc.subjectAlzheimer’s diseaseen
dc.subjectMemoryen
dc.subjectHippocampal volumeen
dc.subjectAmyloiden
dc.subjectMild dementiaen
dc.titlePerformance on the Cogstate Brief Battery Is related to amyloid levels and hippocampal volume in very mild dementiaen
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Molecular Neuroscienceen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationCentre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australiaen
dc.identifier.affiliationSir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australiaen
dc.identifier.affiliationCo-operative Research Centre for Mental Health, Carlton, Victoria, Australiaen
dc.identifier.affiliationDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USAen
dc.identifier.affiliationAcademic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Kew, Victoria, Australiaen
dc.identifier.affiliationNational Ageing Research Institute, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Neurology, Alpert Medical School of Brown University, Providence, RI, USAen
dc.identifier.affiliationCommonwealth Scientific Industrial Research Organization (CSIRO) Preventative Health National Research Flagship, Australian e-Health Research Centre-BiaMedIA, Brisbane, Queensland, Australiaen
dc.identifier.affiliationCogState Ltd., Melbourne, Victoria, Australien
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27586003en
dc.identifier.doi10.1007/s12031-016-0822-8en
dc.type.contentTexten
dc.identifier.orcid0000-0002-2605-4766en
dc.identifier.orcid0000-0003-3910-2453en
dc.type.austinJournal Articleen_US
local.name.researcherMasters, Colin L
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Nov 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.